ARQT

Arcutis Biotherapeutics, Inc.

9.70 USD
+0.02 (+0.21%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arcutis Biotherapeutics, Inc. stock is up 83.02% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 1 PUT, 9 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Feb 17:43 15 Mar, 2024 7.50 PUT 200 216
12 Feb 15:20 16 Feb, 2024 2.50 CALL 90 175
14 Feb 20:53 21 Jun, 2024 2.50 CALL 100 1551
14 Feb 20:54 21 Jun, 2024 2.50 CALL 100 1551
14 Feb 20:56 21 Jun, 2024 2.50 CALL 99 1551
16 Feb 16:09 15 Mar, 2024 10.00 CALL 443 5438
16 Feb 20:54 16 Feb, 2024 7.50 CALL 167 1779
16 Feb 20:55 16 Feb, 2024 7.50 CALL 200 1779
16 Feb 20:58 21 Jun, 2024 12.50 CALL 162 0
26 Feb 20:49 15 Mar, 2024 10.00 CALL 383 5901

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of arq-154.